دورية أكاديمية
Use of the Decipher genomic classifier among men with prostate cancer in the United States.
| العنوان: | Use of the Decipher genomic classifier among men with prostate cancer in the United States. |
|---|---|
| المؤلفون: | Zaorsky NG; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.; Department of Population and Quantitative Health Sciences, Case Western Reserve School of Medicine, Case Western Reserve University, Cleveland, OH, USA., Proudfoot JA; Veracyte, Inc, South San Francisco, CA, USA., Jia AY; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.; Department of Population and Quantitative Health Sciences, Case Western Reserve School of Medicine, Case Western Reserve University, Cleveland, OH, USA., Zuhour R; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.; Department of Population and Quantitative Health Sciences, Case Western Reserve School of Medicine, Case Western Reserve University, Cleveland, OH, USA., Vince R Jr; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.; Department of Population and Quantitative Health Sciences, Case Western Reserve School of Medicine, Case Western Reserve University, Cleveland, OH, USA., Liu Y; Veracyte, Inc, South San Francisco, CA, USA., Zhao X; Veracyte, Inc, South San Francisco, CA, USA., Hu J; Department of Urology, Weil Cornell Medicine, New York, NY, USA., Schussler NC; Information Management Systems, Inc, Calverton, MD, USA., Stevens JL; Information Management Systems, Inc, Calverton, MD, USA., Bentler S; Iowa Cancer Registry, The University of Iowa, IA, USA., Cress RD; Public Health Institute, Cancer Registry of Greater California, Sacramento, CA, USA., Doherty JA; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.; Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA., Durbin EB; Cancer Research Informatics Shared Resource Facility, Markey Cancer Center, Kentucky Cancer Registry, University of Kentucky, Lexington, KY, USA., Gershman S; Massachusetts Cancer Registry, Boston, MA, USA., Cheng I; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA., Gonsalves L; Connecticut Tumor Registry, Connecticut Department of Public Health, Hartford, CT, USA., Hernandez BY; University of Hawaii Cancer Center, HI, USA., Liu L; Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA., Morawski BM; Cancer Data Registry of Idaho, Boise, ID, USA., Schymura M; School of Public Health Epidemiology & Biostatistics, University at Albany, State University of New York, NY, USA., Schwartz SM; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA., Ward KC; Rollins School of Public Health, Emory University, Atlanta, GA, USA., Wiggins C; Department of Internal Medicine, University of NM, Albuquerque, NM, USA., Wu XC; Department of Epidemiology, School of Medicine, Louisiana State University, New Orleans, LA, USA., Shoag JE; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.; Department of Population and Quantitative Health Sciences, Case Western Reserve School of Medicine, Case Western Reserve University, Cleveland, OH, USA., Ponsky L; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.; Department of Population and Quantitative Health Sciences, Case Western Reserve School of Medicine, Case Western Reserve University, Cleveland, OH, USA., Dal Pra A; Department of Radiation Oncology, University of Miami, Miami, FL, USA., Schaeffer EM; Department of Urology, Northwestern University, Chicago, IL, USA., Ross AE; Department of Urology, Northwestern University, Chicago, IL, USA., Sun Y; Department of Population and Quantitative Health Sciences, Case Western Reserve School of Medicine, Case Western Reserve University, Cleveland, OH, USA., Davicioni E; Veracyte, Inc, South San Francisco, CA, USA., Petkov V; Surveillance Research Program, National Cancer Institute, Bethesda, MD, USA., Spratt DE; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.; Department of Population and Quantitative Health Sciences, Case Western Reserve School of Medicine, Case Western Reserve University, Cleveland, OH, USA. |
| المصدر: | JNCI cancer spectrum [JNCI Cancer Spectr] 2023 Aug 31; Vol. 7 (5). |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101721827 Publication Model: Print Cited Medium: Internet ISSN: 2515-5091 (Electronic) Linking ISSN: 25155091 NLM ISO Abbreviation: JNCI Cancer Spectr Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford : Oxford University Press, [2017]- |
| مواضيع طبية MeSH: | Prostatic Neoplasms*/epidemiology , Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/therapy, Male ; Humans ; United States/epidemiology ; Risk Assessment/methods ; Prostate-Specific Antigen ; Prostate/surgery ; Prostate/pathology ; Genomics |
| مستخلص: | Background: Management of localized or recurrent prostate cancer since the 1990s has been based on risk stratification using clinicopathological variables, including Gleason score, T stage (based on digital rectal exam), and prostate-specific antigen (PSA). In this study a novel prognostic test, the Decipher Prostate Genomic Classifier (GC), was used to stratify risk of prostate cancer progression in a US national database of men with prostate cancer. Methods: Records of prostate cancer cases from participating SEER (Surveillance, Epidemiology, and End Results) program registries, diagnosed during the period from 2010 through 2018, were linked to records of testing with the GC prognostic test. Multivariable analysis was used to quantify the association between GC scores or risk groups and use of definitive local therapy after diagnosis in the GC biopsy-tested cohort and postoperative radiotherapy in the GC-tested cohort as well as adverse pathological findings after prostatectomy. Results: A total of 572 545 patients were included in the analysis, of whom 8927 patients underwent GC testing. GC biopsy-tested patients were more likely to undergo active active surveillance or watchful waiting than untested patients (odds ratio [OR] =2.21, 95% confidence interval [CI] = 2.04 to 2.38, P < .001). The highest use of active surveillance or watchful waiting was for patients with a low-risk GC classification (41%) compared with those with an intermediate- (27%) or high-risk (11%) GC classification (P < .001). Among National Comprehensive Cancer Network patients with low and favorable-intermediate risk, higher GC risk class was associated with greater use of local therapy (OR = 4.79, 95% CI = 3.51 to 6.55, P < .001). Within this subset of patients who were subsequently treated with prostatectomy, high GC risk was associated with harboring adverse pathological findings (OR = 2.94, 95% CI = 1.38 to 6.27, P = .005). Use of radiation after prostatectomy was statistically significantly associated with higher GC risk groups (OR = 2.69, 95% CI = 1.89 to 3.84). Conclusions: There is a strong association between use of the biopsy GC test and likelihood of conservative management. Higher genomic classifier scores are associated with higher rates of adverse pathology at time of surgery and greater use of postoperative radiotherapy.In this study the Decipher Prostate Genomic Classifier (GC) was used to analyze a US national database of men with prostate cancer. Use of the GC was associated with conservative management (ie, active surveillance). Among men who had high-risk GC scores and then had surgery, there was a 3-fold higher chance of having worrisome findings in surgical specimens. (© The Author(s) 2023. Published by Oxford University Press.) |
| References: | JAMA Oncol. 2020 Dec 1;6(12):1912-1920. (PMID: 33090219) JCO Precis Oncol. 2018;2:. (PMID: 32832833) Prostate Cancer Prostatic Dis. 2022 Apr;25(4):677-683. (PMID: 34285350) J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52. (PMID: 19815849) J Natl Compr Canc Netw. 2021 Feb 02;19(2):134-143. (PMID: 33545689) Eur Urol. 2016 Jan;69(1):157-65. (PMID: 26058959) Urol Oncol. 2022 Mar;40(3):104.e1-104.e7. (PMID: 34824014) JAMA Oncol. 2021 Jul 01;7(7):1005-1014. (PMID: 34081076) Pract Radiat Oncol. 2020 Mar - Apr;10(2):e82-e90. (PMID: 31761540) J Magn Reson Imaging. 2020 Apr;51(4):1075-1085. (PMID: 31566845) Eur Urol. 2021 Mar;79(3):374-383. (PMID: 33293078) Eur Urol. 2019 Sep;76(3):268-272. (PMID: 31128968) JAMA Oncol. 2021 Apr 1;7(4):544-552. (PMID: 33570548) Ann Oncol. 2021 Sep;32(9):1157-1166. (PMID: 34129855) JAMA Oncol. 2016 Aug 1;2(8):1070-4. (PMID: 27366979) Prostate Cancer Prostatic Dis. 2020 Mar;23(1):136-143. (PMID: 31455846) Am J Surg Pathol. 2016 Dec;40(12):e94-e102. (PMID: 27740970) Cancer Causes Control. 2001 Oct;12(8):703-11. (PMID: 11562110) |
| معلومات مُعتمدة: | HHSN261201800032I United States CA NCI NIH HHS; U54 CA143727 United States CA NCI NIH HHS; HHSN261201800016I United States CA NCI NIH HHS; HHSN261201800013I United States CA NCI NIH HHS; P30 CA177558 United States CA NCI NIH HHS; HHSN261201800012C United States CA NCI NIH HHS; HHSN261201300009I United States CA NCI NIH HHS; HHSN261201800006I United States CA NCI NIH HHS; HHSN261201800014I United States CA NCI NIH HHS; U54 CA143728 United States CA NCI NIH HHS; HHSN261201800012I United States CA NCI NIH HHS |
| المشرفين على المادة: | EC 3.4.21.77 (Prostate-Specific Antigen) |
| تواريخ الأحداث: | Date Created: 20230801 Date Completed: 20230918 Latest Revision: 20240703 |
| رمز التحديث: | 20240703 |
| مُعرف محوري في PubMed: | PMC10505256 |
| DOI: | 10.1093/jncics/pkad052 |
| PMID: | 37525535 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2515-5091 |
|---|---|
| DOI: | 10.1093/jncics/pkad052 |